Results 91 to 100 of about 38,166 (233)

Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial

Human Vaccines & Immunotherapeutics, 2017
Background: The type 2 component of the oral poliovirus vaccine is targeted for global withdrawal through a switch from the trivalent oral poliovirus vaccine (tOPV) to a bivalent oral poliovirus vaccine (bOPV). The switch is intended to prevent paralytic
Jingjun Qiu, Yunkai Yang, Lirong Huang, Ling Wang, Zhiwei Jiang, Jian Gong, Wei Wang, Hongyan Wang, Shaohong Guo, Chanjuan Li, Shuyuan Wei, Zhaojun Mo, Jielai Xia   +12 more
doaj   +1 more source

Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden

BMJ Global Health, 2019
Background Our understanding of the acquisition of intestinal mucosal immunity and the control of poliovirus replication and transmission in later life is still emerging.Methods As part of a 2011 randomised, blinded, placebo-controlled clinical trial of ...
Elizabeth B Brickley, Ruth I Connor, Wendy F Wieland-Alter, Marc S Collett, Marianne Hartford, Harrie Van Der Avoort, Austin W Boesch, Joshua A Weiner, Margaret E Ackerman, Mark A McKinlay, Minetaro Arita, Ananda S Bandyopadhyay, John F Modlin, Peter F Wright   +13 more
doaj   +1 more source

Exploring the Role of Pattern Recognition Receptors as Immunostimulatory Molecules

Immunity, Inflammation and Disease, Volume 13, Issue 5, May 2025.
This mini‐review summarizes different classes of pattern recognition receptors (PRRs) and the role of their agonizts that have been identified and also outlines the role of PRR ligands as immunostimulatory molecules. Overall, the mini‐review has elaborated on the role of PRRs in the development of therapeutic vaccine adjuvants.
Meenal Sharma, Priyanka Wagh, Tanvi Shinde, Diptee Trimbake, Anuradha S. Tripathy   +4 more
wiley   +1 more source

Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification?

Bulletin of the World Health Organization, 2004
The absolute laboratory containment of any virus cannot be guaranteed, but a wealth of experience indicates that effective containment of wild poliovirus materials for global certification is technically and operationally feasible.
Dowdle Walter R., Wolff Christopher, Sanders Raymond, Lambert Scott, Best Maureen   +4 more
doaj  

Vaccine-associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006-2013 y.y.)

Вопросы вирусологии, 2016
The results of virologic testing of clinical materials and epidemiological analysis of vaccine-associated paralytic poliomyelitis (VAPP) cases obtained in 2006-2013 during AFP surveillance are presented. Among the 2976 cases of AFP 30 cases were vapp. 15
O. E. Ivanova, T. P. Eremeeva, N. S. Morozova, A. K. Shakaryan, A. P. Gmyl, M. L. Yakovenko, E. A. Korotkova, O. P. Chernjavskaja, O. Yu. Baykova, O. V. Silenova, A. Yu. Krasota, L. I. Krasnoproshina, A. N. Mustafina, L. I. Kozlovskaja   +13 more
doaj   +1 more source

The role of the gut microbiota in regulating responses to vaccination: current knowledge and future directions

The FEBS Journal, Volume 292, Issue 6, Page 1480-1499, March 2025.
Vaccination plays a crucial role in mediating protection against infectious diseases, but immune responses to vaccination are highly variable and frequently sub‐optimal in vulnerable populations. Here, we review the latest preclinical and clinical evidence demonstrating that the gut microbiota plays a significant role in regulating immune responses to ...
Charné Rossouw, Feargal J. Ryan, David J. Lynn   +2 more
wiley   +1 more source

Antigenic structure of poliovirus in inactivated vaccines

Journal of General Virology, 1993
The reactivity of D antigen-specific monoclonal antibodies with infectious virus and inactivated virus in commercial poliovaccines from two manufacturers was examined in capture enzyme immunoassays. Epitopes on inactivated poliovirus types 2 and 3 in vaccines were modified by the inactivation process to such an extent that some monoclonal antibodies ...
M, Ferguson, D J, Wood, P D, Minor
openaire   +2 more sources

Insights Into Enterovirus D68 Immunology: Unraveling the Mysteries of Host‐Pathogen Interactions

Immunity, Inflammation and Disease, Volume 13, Issue 2, February 2025.
This review provides a comprehensive overview of the immunological responses to Enterovirus D68, offering valuable insights for researchers, clinicians, and public health professionals working towards effective prevention and control strategies. ABSTRACT Background Enterovirus D68 (EV‐D68) has emerged as a significant respiratory and neurological ...
Asif Naeem, Muhammad Bashir Bello, Mohammad Bosaeed   +2 more
wiley   +1 more source

Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.

Journal of Infectious Diseases, 2019
BACKGROUND In July 2016, Sri Lanka replaced 1 intramuscular dose of inactivated poliovirus vaccine (IPV) with 2 doses of intradermal fractional-dose IPV (fIPV) in its routine immunization schedule.
D. Gamage, O. Mach, S. Ginige, W. Weldon, M. Oberste, V. Jeyaseelan, R. Sutter   +6 more
semanticscholar   +1 more source

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

PLoS ONE, 2016
BackgroundThe "gold standard" for assessing mucosal immunity after vaccination with poliovirus vaccines consists in measuring virus excretion in stool after challenge with oral poliovirus vaccine (OPV).
Ayan Dey, Natalie A Molodecky, Harish Verma, Prashant Sharma, Jae Seung Yang, Giulietta Saletti, Mohammad Ahmad, Sunil K Bahl, Thomas F Wierzba, Ranjan K Nandy, Jagadish M Deshpande, Roland W Sutter, Cecil Czerkinsky   +12 more
doaj   +1 more source